OBTN

The Trials in Progress section supploes summaries of ongoing research in a broad range of cancer types.

FDA updates for the Month of March

Though taking multivitamins has been linked to potential health benefits, a new study has found that an excessive consumption of multivitamins may not be beneficial.

Recent reports published in the Childhood Cancer Survivor Study (CCSS) are examining the longterm or delayed health effects of cancer treatments.

That human touch and caring makes a big difference for people

New research has shown that adding prompt palliative supportive care to standard treatment may not only improve mood and quality of life in cancer patients, but it may even extend survival.

The FDA has given Merit Medical Systems the green light for a phase III clinical trial investigating QuadraSphere Microspheres in patients with primary liver cancer.

The FDA has requested that the generic drug manufacturer Hospira change the planned label for its generic formulation of docetaxel.

The FDA has notified Spectrum Pharmaceuticals that it will decide whether to approve Fusilev (levoleucovorin) for colorectal cancer within 6 months.

The FDA has released briefing documents noting that the 5-alpha reductase inhibitor increases the risk of high-risk prostate cancer.

An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease.

An article in Oncogene further explains how ultraviolet (UV) radiation helps transform skin cells into basal cell carcinoma.

A recent poll conducted by Britain's Royal Society found that what Britons want most is a vaccine that will prevent cancer.

A Web-based CME program gives physicians in rural areas free access to clinical research and expert advice on oncology through an e-newsletter.

A retrospective study conducted at Stanford University found that the risk of cancer due to radiation from CT scans might be lower than previously determined.

Coloring for Chemo/Comfort is a nonprofit organization in Nevada started by Amy Villarele-Hardy and Nina Lawyer in November 2009.

According to the British Journal of Cancer, a new study by London's Institute of Cancer Research finds that finger length might be an indicator of prostate cancer risk.

The Sylvester Comprehensive Cancer Center (SCCC), part of the University of Miami Health System, first opened its doors in 1992. Over the years, the SCCC has become the hub of cancer research in the region.